ReviewScience China. Life sciences2026
Chemical adaptation: bridging synthetic chemistry with drug development.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Structure-based drug design (SBDD) has profoundly advanced the rational development of small molecule therapeutics by enabling the systematic optimization of drug-target interactions. A variety of molecular recognition models provide conceptual frameworks for understanding these interactions, thereby facilitating improvements in binding affinity, target selectivity, and pharmacokinetic profiles-key determinants of clinical success. To better emphasize the chemical nature of these interactions and to enhance the accessibility of rational drug design concepts for the synthetic chemistry community, we introduce chemical adaptation as a complementary framework to SBDD, offering an alternative, chemistry-oriented perspective for interpreting ligand-target interactions. This concept highlights deliberate, chemically driven strategies for optimizing ligand binding and improving drug-like characteristics. We classify chemical adaptation into four principal categories: ligand template adaptation (aligning the ligand's core structure with the topology of the target binding pocket), scaffold steric adaptation (refining the spatial orientation and steric complementarity of the molecular scaffold), functional group adaptation (modulating non-covalent interactions and physicochemical properties), and proximity-induced reactivity adaptation (leveraging covalent reactivity to strengthen target engagement). Collectively, these strategies underscore the necessity of precisely tailoring ligand structures to achieve optimal drug-like properties and offer a versatile, chemistry-centered framework applicable to the design of small molecule drugs across a broad spectrum of biological targets and therapeutic modalities.
Indexed as
Identifiers
41979785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.